Cannabinoid Therapeutics

Cannabinoid Therapeutics

In Vivo Preclinical CRO Services for Cannabinoid-Based Therapeutics

Anilocus provides a comprehensive set of preclinical in vivo research services for the development of cannabinoid-based therapeutics. Utilizing our advanced technology and pharmacology expertise, Anilocus can assist in the development of drug products that modulate the endocannabinoid system.

With this, potential cannabinoid-based drug treatments for various diseases and conditions can be assessed in vivo. The most abundant phytocannabinoids, such as THC and CBD, can be assessed for their activity through assays  G-protein-mediated mechanisms and their safety and efficacy through multiple different formulations. Anilocus can help researchers unlock the therapeutic potential of these compounds in a wide range of treatments.

Our preclinical in vivo research services are reproducible, efficient, and comprehensive, making our team an invaluable resource for Sponsors.

Contact us! Learn more about our in vivo services for cannabinoid-based therapies:

    With our team, we make it possible for Sponsors to make informed decisions about developing cannabinoid-based therapies for patients with cancer, neurodegenerative disorders, dermatological diseases, and infectious diseases.

    Team Anilocus - Preclinical contract research organization (CRO) based in San Diego, California | In vivo research services

    Our benefits

    What We Offer at Anilocus:

    Multiple animal models are used in preclinical product development of cannabinoid-based therapies including:

    • Gene knockout/knockin/trapped
    • Transgenic rodents
    • Chemically-Induced Point Mutation rodents
    • Stress-induced models
    • Drug-Induced models
    • Wound/Laceration Models
    • Postpartum Depressive-Like Model
    • Autism-like Models
    • Chronic pain Models
    • Metabolic Dysfunction Models (Diet restriction, Metabolic disorders, micronutrient deficient)
    • And more…

    We conduct translational in vivo animal studies collecting detailed, comprehensive results with rapid turnaround.

    Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?

    At AniLocus, we conduct relevant preclinical studies to validate any drug modality:

    • Antibodies (nanobodies, monoclonal)
    • Gene therapy (CRISPR, TALEN)
    • Viral therapy (adenovirus-AAV, lentivirus)
    • Oligo- and polypeptides (e.g., stapled and modified peptides)
    • Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
    • Polyglycosides
    • Macrocyclic molecules
    • Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
    • Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
    • Cellular therapies (stem cells, allogenic, autologous)

    We can perform multiple interrogative assays for any therapeutic area and sample type:

    • DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
    • RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
    • Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and  immunofluorescence (IF)
    • And more!
    1. Klein TA, Clark CS. Therapeutic use of cannabis in the US. Nurse Pract. 2022;47(12):16-25. doi:10.1097/01.NPR.0000884880.81603.c5.
    2. Schurman LD, Lu D, Kendall DA, Howlett AC, Lichtman AH. Molecular Mechanism and Cannabinoid Pharmacology. Handb Exp Pharmacol. 2020;258:323-353. doi:10.1007/164_2019_298.
    3. Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep. 2020;10(1):20405. Published 2020 Nov 23. doi:10.1038/s41598-020-77175-y
    4. Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci. 2022;23(6):3344. Published 2022 Mar 19. doi:10.3390/ijms23063344.
    5. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. doi:10.1111/bcp.13710